News Releases
by Category
Products
Aug. 08, 2022 (PDF/272KB) Products
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
May 02, 2022 (PDF/40KB) Products
Myovant Sciences Announces European Commission Approval for ORGOVYX (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
Oct. 11, 2021 (PDF/344KB) Products
Enzyvant Receives FDA Approval for RETHYMIC (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
Sep. 10, 2021 (PDF/120KB) Products
Sumitomo Dainippon Pharma Announces Launch of TWYMEEG for the Treatment of Type 2 Diabetes in Japan
Jul. 20, 2021 (PDF/41KB) Products
Myovant Sciences Announces European Commission Approval for RYEQO for the Treatment of Women With Uterine Fibroids
Jun. 23, 2021 (PDF/221KB) Products
Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan
May 27, 2021 (PDF/172KB) Products
Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
Apr. 13, 2021 (PDF/81KB) Products
Urovant Sciences Announces U.S. Commercial Launch of GEMTESA (vibegron) 75 mg Tablets for Patients with Overactive Bladder
Jan. 06, 2021 (PDF/84KB) Products
Myovant Sciences Announces U.S. Availability of ORGOVYX for the Treatment of Advanced Prostate Cancer
Dec. 24, 2020 (PDF/93KB) Products
Urovant Sciences Announces U.S. FDA Approval of GEMTESA (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
Dec. 21, 2020 (PDF/102KB) Products
Myovant Sciences Announces FDA Approval of ORGOVYX (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
Oct. 06, 2020 (PDF/275KB) Products
Sunovion Announces the Commercial Launch of KYNMOBI (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes
Jun. 16, 2020 (PDF/516KB) Products
Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson's Disease OFF Episodes
Jun. 04, 2020 (PDF/161KB) Products
Sumitomo Dainippon Pharma Announces Launch of Atypical Antipsychotic Agent, LATUDA Tablets in Japan
May 22, 2020 (PDF/895KB) Products
Sunovion Announces U.S. FDA Approval of KYNMOBI (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes
Mar. 25, 2020 (PDF/107KB) Products
Sumitomo Dainippon Pharma Announces Approval of Atypical Antipsychotic Agent, LATUDA Tablets in Japan
Mar. 25, 2020 (PDF/164KB) Products
Sumitomo Dainippon Pharma Announces the Approval of RETHIO for an Additional Indication of Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
Sep. 03, 2019 (PDF/82KB) Products
Sumitomo Dainippon Pharma to Launch Atypical Antipsychotic LONASEN Tape in Japan
Sep. 03, 2019 (PDF/106KB) Products
Sumitomo Dainippon Pharma Announces the Launch of Atypical Antipsychotic LATUDA in China
Jun. 18, 2019 (PDF/87KB) Products
Sumitomo Dainippon Pharma and Nitto Denko Announce the Approval of Atypical Antipsychotic LONASEN Tape in Japan
May 22, 2019 (PDF/86KB) Products
Sumitomo Dainippon Pharma to Launch RETHIO for Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation
Mar. 26, 2019 (PDF/49KB) Products
Sumitomo Dainippon Pharma Receives Approval in Japan for RETHIO for Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation
Jan. 29, 2019 (PDF/39KB) Products
Sumitomo Dainippon Pharma Announces the Approval of Atypical Antipsychotic Latuda (lurasidone HCl) for the Treatment of Patients with Schizophrenia in China
Jul. 02, 2018 (PDF/126KB) Products
Sumitomo Dainippon Pharma Obtains Approval in Japan for TRERIEF, a therapeutic agent for Parkinson's disease, for an Additional Indication of Parkinsonism in Dementia with Lewy Bodies
Apr. 04, 2018 (PDF/323KB) Products
Sunovion Announces Lonhala Magnair (glycopyrrolate) Inhalation Solution Now Available in the U.S. for the Treatment of COPD
Mar. 07, 2018 (PDF/369KB) Products
Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
Mar. 01, 2018 (PDF/156KB) Products
Pfizer and Sumitomo Dainippon Pharma Commence the Co-Promotion of Serotonin-Norepinephrine Reuptake Inhibitor EFFEXOR SR Capsules
Feb. 01, 2018 (PDF/129KB) Products
Sumitomo Dainippon Pharma Announces an Atypical Antipsychotic LONASEN is Now Available in China
Dec. 06, 2017 (PDF/300KB) Products
Sunovion Receives FDA Approval for Lonhala Magnair Inhalation Solution to Treat COPD
Oct. 20, 2017 (PDF/348KB) Products
Sunovion Announces Seebri Neohaler (glycopyrrolate) Inhalation Powder is Now Available in the United States
Sep. 15, 2017 (PDF/365KB) Products
Sunovion's Aptiom (eslicarbazepine acetate) Receives FDA Approval for Expanded Indication to Treat Partial-Onset Seizures in Children and Adolescents 4 Years of Age and Older
May 31, 2017 (PDF/180KB) Products
Toray's Pruritus Treatment REMITCH OD Tablets 2.5 μg to Be Introduced in Japan
Apr. 04, 2017 (PDF/347KB) Products
Sunovion Announces Utibron Neohaler (indacaterol/glycopyrrolate) Inhalation Powder Now Available in the United States
Mar. 30, 2017 (PDF/109KB) Products
Toray Receives Japanese Approval for an Additional Formulation of Pruritus Treatment REMITCH OD TABLETS 2.5μg
Feb. 28, 2017 (PDF/88KB) Products
Sumitomo Dainippon Pharma Announces the Approval of an Atypical Antipsychotic Blonanserin (Brand Name in Japan: LONASEN) in China
Jan. 28, 2017 (PDF/295KB) Products
Sunovion’s Latuda (lurasidone HCl) Receives FDA Approval to Treat Adolescents with Schizophrenia
Nov. 10, 2015 (PDF/187KB) Products
Received the Award for the First Time with the Pen-Style Medical Injector. A Unique Injector, "Ateos" for "Trulicity" Type 2 Diabetes Treatment Received "Good Design Gold Award."
Sep. 30, 2015 (PDF/152KB) Products
"Ateos" Injector for "Trulicity" Type 2 Diabetes Treatment Wins "Good Design Award 2015" and Selected as One of Good "Design Best 100 2015"
Sep. 16, 2015 (PDF/183KB) Products
Market Release of "Trulicity Subcutaneous Injection 0.75mg Ateos"Once-Weekly Type 2 Diabetes Treatment ： GLP-1 Receptor Agonist
Aug. 28, 2015 (PDF/184KB) Products
Sunovion Announces FDA Approval of a New Indication for Aptiom (eslicarbazepine acetate) as Monotherapy for Partial-Onset Seizures
May 20, 2015 (PDF/117KB) Products
Toray Receives Japanese Approval for Additional Indication of Pruritus Treatment REMITCH CAPSULES 2.5 μg and Promotion to Start
Mar. 03, 2015 (PDF/114KB) Products
Toray Applies for Japanese Approval of Additional Indication of Pruritus Treatment REMITCH CAPSULES 2.5 μg and Notice Regarding Promotion Tie-up
Nov. 18, 2014 (PDF/219KB) Products
Sumitomo Dainippon Pharma obtains Approval in Japan for Partial Change of the Approved Indication to "Type 2 Diabetes" for SUREPOST, a Rapid-acting Insulin Secretagogue
Oct. 20, 2014 (PDF/101KB) Products
Announcement of termination of co-promotion of anti-depressant, Paxil CR Tablets
Aug. 21, 2014 (PDF/202KB) Products
Latuda (lurasidone), a New Atypical Antipsychotic Agent for Adults with Schizophrenia, Now Available in the UK, Offers a Combination of Efficacy with Tolerability
Jul. 11, 2014 (PDF/168KB) Products
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
Apr. 07, 2014 (PDF/192KB) Products
Once-Daily Aptiom (eslicarbazepine acetate) for the Adjunctive Treatment of Partial-Onset Seizures Now Available in U.S. Pharmacies
Apr. 03, 2014 (PDF/126KB) Products
Dainippon Sumitomo Pharma Announces Health Canada Approval of LATUDA (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Patients with Bipolar Depression
Mar. 31, 2014 (PDF/131KB) Products
Dainippon Sumitomo Pharma and Takeda Announce the European Marketing Authorization for Latuda (lurasidone) - a New Atypical Antipsychotic Medication for Adults with Schizophrenia
Mar. 25, 2014 (PDF/120KB) Products
Dainippon Sumitomo Pharma Announces the Marketing Authorization in Australia for Atypical Antipsychotic Agent Latuda
Feb. 19, 2014 (PDF/178KB) Products
Chelsea Therapeutics Obtains US FDA Accelerated Approval on "NORTHERA"
Dec. 20, 2013 (PDF/66KB) Products
Dainippon Sumitomo Pharma obtains approval in Japan of a partial change in the approved dosage and administration of MEROPEN, a carbapenem antibiotic preparation, when used for the treatment of bacterial meningitis
Dec. 09, 2013 (PDF/113KB) Products
Sunovion Pharmaceuticals Inc. Presents Phase 3 Pooled Analysis of Once-Daily Aptiom (eslicarbazepine acetate) as Adjunctive Treatment for Partial-Onset Seizures
Nov. 08, 2013 (PDF/42KB) Products
Sunovion Pharmaceuticals Inc. Announces FDA Approval of Aptiom (eslicarbazepine acetate) as Once-Daily Adjunctive Treatment of Partial-Onset Seizures
Nov. 01, 2013 (PDF/110KB) Products
Sunovion Announces Publication of Two Pivotal Studies Supporting FDA Approval of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression in The American Journal of Psychiatry
Aug. 13, 2013 (PDF/65KB) Products
DSP and Takeda Announce Approval of the Marketing Authorization Application for Atypical Antipsychotic Agent Lurasidone in Switzerland
Jun. 29, 2013 (PDF/115KB) Products
Sunovion Pharmaceuticals Inc. Announces FDA Approval of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression
Jun. 12, 2013 (PDF/47KB) Products
Dainippon Sumitomo Pharma announces the launch of anti-hypertension drug "AVAPRO Tablets 200mg"
Feb. 28, 2013 (PDF/48KB) Products
Dainippon Sumitomo Pharma obtains approval for SUREPOST, a rapid-acting insulin secretagogue, for the additional indications of combination therapy with biguanides and with thiazolidinediones
Nov. 22, 2012 (PDF/64KB) Products
Dainippon Sumitomo Pharma and Shionogi Announce the NHI Drug Price Standard Listing and Launch of anti-hypertension drug "AIMIX Combination Tablets LD/HD"
Sep. 28, 2012 (PDF/72KB) Products
Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for "AIMIX Combination Tablets LD/HD"
Sep. 18, 2012 (PDF/164KB) Products
Sunovion Pharmaceuticals Canada Inc. Announces the Launch of Once-Daily Latuda (lurasidone HCl) for the Treatment of Patients with Schizophrenia
Jul. 31, 2012 (PDF/102KB) Products
Sunovion Pharmaceuticals Inc. Announces Nationwide Availability of ZETONNA (ciclesonide) Nasal Aerosol for Allergic Rhinitis
Jul. 27, 2012 (PDF/51KB) Products
SUNOVION PHARMACEUTICALS RECEIVES SIX MONTH U.S. PEDIATRIC EXCLUSIVITY FOR LUNESTA (eszopiclone)
Jun. 26, 2012 (PDF/105KB) Products
Dainippon Sumitomo Pharma announces the launch of Sleep Inducing Treatment "Zolpidem tartrate tablets 5mg/10mg [DSP]"
Jun. 22, 2012 (PDF/88KB) Products
Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for long-acting calcium antagonist AMLODIN tablets/OD tablets for the Additional Indication of "Hypertension in pediatric patients"
Jun. 22, 2012 (PDF/114KB) Products
Anti-depressant Paxil CR Tablets newly launched
Jun. 16, 2012 (PDF/25KB) Products
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of Once-Daily LATUDA (lurasidone HCl) for the Treatment of Patients with Schizophrenia
May 10, 2012 (PDF/113KB) Products
New Study Shows Patients Can Effectively be Switched to Latuda (lurasidone HCl) from Other Antipsychotic Agents
May 08, 2012 (PDF/93KB) Products
SUNOVION ANNOUNCES UPCOMING AVAILABILITY OF ZETONNA (ciclesonide) NASAL AEROSOL, A NON-AQUEOUS, DRY NASAL AEROSOL SPRAY FOR ALLERGIC RHINITIS
May 07, 2012 (PDF/94KB) Products
Latuda (lurasidone HCl) Label Updated With Expanded Dosing Range Providing Added Flexibility for the Treatment of Patients with Schizophrenia
Mar. 30, 2012 (PDF/90KB) Products
GlaxoSmithKline and Dainippon Sumitomo Pharma commence the co-promotion of anti-depressant Paxil CR Tablets
Feb. 20, 2012 (PDF/105KB) Products
Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for Sleep Inducing Treatment "Zolpidem tartrate tablets 5mg/10mg [DSP]"
Jan. 19, 2012 (PDF/98KB) Products
Announcement of basic agreement concerning co-promotion of anti-depressant Paxil® CR Tablets
Dec. 01, 2011 (PDF/25KB) Products
Dainippon Sumitomo Pharma and Yoshitomiyakuhin terminate co-promotion of antipsychotics, LONASEN and LULLAN
Nov. 28, 2011 (PDF/90KB) Products
Dainippon Sumitomo Pharma announces the launch of Alzheimer's Disease Treatment Donepezil hydrochloride tablets/OD tablets 3mg/5mg "DSP"
Jul. 19, 2011 (PDF/103KB) Products
Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for Alzheimer's Disease Treatment "Donepezil hydrochloride tablets/OD tablets 3mg/5mg [DSP]".
May 09, 2011 (PDF/81KB) Products
Dainippon Sumitomo Pharma announces the launch of SUREPOST, a rapid-acting insulin secretagogue
Mar. 10, 2011 (PDF/79KB) Products
Approval obtained for partial change in dosage and administration of MEROPEN, a carbapenem antibiotic preparation
Feb. 03, 2011 (PDF/47KB) Products
Dainippon Sumitomo Pharma Co. Ltd. (DSP) Announces Launch of Latuda (lurasidone HCl) in the United States
Jan. 21, 2011 (PDF/51KB) Products
SUREPOST, a rapid-acting insulin secretagogue, obtains a manufacturing and marketing approval
Dec. 09, 2010 (PDF/138KB) Products
Latuda (lurasidone HCl) Significantly Improves Symptoms of Schizophrenia in Fifth Positive Placebo-Controlled Study
Oct. 29, 2010 (PDF/118KB) Products
FDA APPROVES ONCE-DAILY LATUDA (lurasidone HCL) FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA
Oct. 04, 2010 (PDF/50KB) Products
Notice of launching of LONASEN in Korea
Apr. 23, 2010 (PDF/46KB) Products
Notice of launching of LONASEN tablets 8mg
Apr. 22, 2010 (PDF/51KB) Products
Launch of oral hypoglycemic drug METGLUCO
Jan. 20, 2010 (PDF/69KB) Products
Acquisition of an additional indication of MEROPEN, a carbapenem antibiotic preparation
Jan. 20, 2010 (PDF/41KB) Products
Oral hypoglycemic drug METGLUCO obtained a manufacturing and marketing approval
Dec. 18, 2009 (PDF/46KB) Products
SEPRACOR GRANTED PATENT TERM EXTENSION FOR LUNESTA AND PROVIDES UPDATE ON LUNESTA PEDIATRIC STUDIES
Dec. 15, 2009 (PDF/52KB) Products
Notice of launching of therapeutic agent for hepatocellular carcinoma "MIRIPLA"
Oct. 16, 2009 (PDF/50KB) Products
Therapeutic agent for hepatocellular carcinoma "MIRIPLA" obtained manufacturing and marketing approval
Sep. 11, 2009 (PDF/65KB) Products
New OD tablet of AMLODIN by original formulation technology "SUITAB-NEX"
Jun. 19, 2009 (PDF/57KB) Products
Acquisition of an additional indication of AmBisome, a therapeutic agent for systemic fungal infection
Apr. 22, 2009 (PDF/62KB) Products
Acquisition of an additional indication relating to pretreatment for barium enema X-ray examination by concomitant use of NIFLEC and GASMOTIN
Mar. 13, 2009 (PDF/75KB) Products
Notice of launching of a new Parkinson's disease drug "TRERIEF"
Jan. 21, 2009 (PDF/49KB) Products
Parkinson's disease drug "TRERIEF" obtained manufacturing and marketing approval
Jun. 23, 2008 (PDF/39KB) Products
Notice of launching of Anti-hypertension drug "AVAPRO"
Apr. 21, 2008 (PDF/15KB) Products
Notice of launching of a new antipsychotic LONASEN
Apr. 17, 2008 (PDF/33KB) Products
Anti-hypertension drug "Avapro" obtained manufacturing and marketing approval
Feb. 14, 2007 (PDF/96KB) Products
Launch of "Replagal3.5mg" for Anderson-Fabry Disease
Aug. 03, 2006 (PDF/29KB) Products
Conclusion of an Agreement over Co-promotion of Dops for the Treatment of Orthostatic Hypotension
Jun. 15, 2006 (PDF/91KB) Products
Launch of AmBisome 50mg for Intravenous Drip Infusion, a Therapeutic Agent for Systemic Fungal Infection
Mar. 27, 2006 (PDF/17KB) Products
Pending Expiration of Cooperative Marketing Agreement between Abbott Japan and Dainippon Sumitomo Pharma